---
schema_version: "secwatch.filing_event.v1"
accession: "0001714899-26-000042"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2026-04-03T23:59:59+00:00"
generated_at: "2026-05-15T07:38:17.535943+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Denali regains full rights to DNL593 after Takeda terminates collaboration

## Summary
- Takeda terminated co-development agreement for DNL593 (PTV:PGRN) effective 60 days from April 3, 2026; reason is strategic, not safety/efficacy.
- Denali will continue Phase 1/2 study independently; results expected by end of 2026.
- Enrollment complete with 40 FTD-GRN participants; interim data showed dose-dependent CSF progranulin increases and favorable tolerability.
- Denali has no further financial obligations to Takeda post-termination and retains full intellectual property rights.
- DNL593 uses TransportVehicle platform, first FDA-approved BBB-crossing technology, addressing FTD-GRN with no approved slowing treatments.

## SEC filing metadata
- accession: 0001714899-26-000042
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2026-04-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000042/0001714899-26-000042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000042/dnli-20260403.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001714899-26-000042
- JSON: https://secwatch.observer/filing/0001714899-26-000042.json
- Plain text: https://secwatch.observer/filing/0001714899-26-000042.txt

## Source-grounded claims
- claim_id: 46075dd6773bc1952c31309ead0ab7260218210b
  claim: Denali Therapeutics Inc. terminated Collaboration Agreement with Takeda Pharmaceutical Company Limited (effective 2018-01-03).
  evidence_excerpt: On April 3, 2026, Denali Therapeutics Inc. (“Denali”) received written notice from Takeda Pharmaceutical Company Limited (“Takeda”) of its decision to terminate the Collaboration Agreement (the “Agreement”), dated January 3, 2018, between the two companies to co-develop and co-commercialize DNL593 (PTV:PGRN).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000042/0001714899-26-000042-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.